Centene Co. (NYSE:CNC) Position Lessened by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. reduced its position in Centene Co. (NYSE:CNC) by 13.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 979,994 shares of the company’s stock after selling 157,858 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Centene were worth $73,774,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Park Place Capital Corp increased its stake in shares of Centene by 1,190.0% during the 3rd quarter. Park Place Capital Corp now owns 387 shares of the company’s stock worth $29,000 after purchasing an additional 357 shares during the last quarter. WR Wealth Planners LLC raised its holdings in Centene by 41.4% during the second quarter. WR Wealth Planners LLC now owns 468 shares of the company’s stock valued at $31,000 after buying an additional 137 shares in the last quarter. Chris Bulman Inc acquired a new stake in shares of Centene in the second quarter worth about $33,000. Riverview Trust Co increased its holdings in shares of Centene by 154.6% during the 2nd quarter. Riverview Trust Co now owns 527 shares of the company’s stock valued at $35,000 after acquiring an additional 320 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Centene in the 2nd quarter worth approximately $36,000. 93.63% of the stock is owned by hedge funds and other institutional investors.

Centene Stock Up 0.5 %

NYSE:CNC opened at $63.82 on Tuesday. Centene Co. has a 52-week low of $59.77 and a 52-week high of $81.42. The stock’s fifty day moving average price is $70.97 and its two-hundred day moving average price is $71.89. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.17 and a current ratio of 1.10. The company has a market cap of $32.22 billion, a price-to-earnings ratio of 11.08, a P/E/G ratio of 0.85 and a beta of 0.49.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Sanford C. Bernstein dropped their price target on shares of Centene from $96.00 to $88.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 30th. Oppenheimer reduced their price target on shares of Centene from $110.00 to $95.00 and set an “outperform” rating for the company in a report on Monday, July 29th. JPMorgan Chase & Co. cut their price objective on shares of Centene from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Barclays lowered their price target on Centene from $97.00 to $91.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 29th. Finally, TD Cowen upped their target price on shares of Centene from $80.00 to $89.00 and gave the stock a “buy” rating in a report on Wednesday, July 31st. Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Centene currently has a consensus rating of “Moderate Buy” and an average target price of $83.92.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.